The clinical investigators specifically noted that "gastrointestinal adverse events were partially mitigated by the use of a lower starting dose." Starting at 1 mg, which is what the Phase 3 TRIUMPH trials use, provides even more tolerability protection
6.2 Modulation of gut microbiota Recent research suggests that GLP-1 receptor agonists significantly affect the composition of gut microbiota, revealing a new mechanism that contributes to metabolic advantages (Liang et al
Key takeaways for mums: GLP-1 medications are not safe to take while breastfeeding
However, many are surprised by how small and fine it actually is
But that drug is a peptide, delivering semaglutide in a large-molecule form that is harder to manufacture and requires more care when taking it
P =0.24), colon cancer (RR, 0.73